The finding that MR-409 induced the expression of insulin receptor substrate 2 (IRS2), a master regulator of β-cell survival and growth, suggests the potential benefits of the GHRH agonist in type 2 diabetes (T2D) [48]. The gene discussed is IRS2; the disease is type 2 diabetes mellitus.